Le Lézard
Classified in: Health
Subjects: RCL, CFG

Public Advisory - Recall of one lot of Jamp-Atorvastatin Calcium as some bottles may be labelled as containing 10 mg tablets, but contain 40 mg tablets


OTTAWA, ON, Aug. 27, 2022 /CNW/ -

Summary
Photos

Jamp-Atorvastatin Calcium 10 mg tablets (CNW Group/Health Canada)

Jamp-Atorvastatin Calcium 40 mg tablets (CNW Group/Health Canada)

Affected products

Product

Company

DIN

Lot

Expiry Date

Jamp-Atorvastatin Calcium

10 mg tablets

 

Jamp Pharma Corporation

02504197

D10776B

06/2023

Jamp-Atorvastatin Calcium

40 mg tablets

Jamp Pharma Corporation

02504219

D10776B

06/2023

 

Issue

Jamp Pharma Corporation is recalling one lot (D10776B) of Jamp-Atorvastatin Calcium after one bottle labelled to contain 10 mg tablets of Jamp-Atorvastatin Calcium was found to contain 40 mg tablets of Jamp-Atorvastatin Calcium.

Pharmacists may not recognize the error and accidentally repackage and dispense bottles to patients that are labelled as 10 mg atorvastatin calcium tablets (DIN 02504197), but incorrectly contain 40 mg atorvastatin calcium tablets.

Product from the affected lot was sold to pharmacies between May 2022 and August 2022.

Both the 10 mg and 40 mg atorvastatin calcium tablets are similar-looking white and oval shaped tablets; however, the 10 mg tablets have a "10" marked on one side while the 40 mg tablets have a "40" marked on one side. 

Atorvastatin calcium is a prescription drug in the class of statins used to lower cholesterol and other fats in the blood and for prevention of cardiovascular disease such as heart attacks.

Taking too much atorvastatin calcium or more than the prescribed amount for a long period of time (i.e., taking 40 mg of atorvastatin calcium instead of 10 mg atorvastatin calcium) can increase the risk of serious adverse events, including muscle pain or muscle weakness (i.e., rhabdomyolysis, a rare but serious adverse event associated with statins).

The Department is monitoring the company's recall and will inform the public if any new health risks are identified.

What you should do
Additional information for health care professionals:

Alert / recall type: Public Advisory
Category: Health products ? Drugs
Published by: Health Canada

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 11:00
PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") , a biotechnology company focused on the research, development, and manufacturing of LaNeotm MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to announce that it has...

at 11:00
MyAdvisor, a holistic wellness company, is pleased to announce the opening of a new office in Bedford, Pennsylvania. This strategic expansion is driven by the company's sustained growth and commitment...

at 11:00
Mozart Therapeutics, the leading developer of CD8 Treg network modulators, today announce the release of new pre-clinical data for their second program, a KIR x ICOS bispecific antibody targeting CD8 regulatory T cells. The data will be presented...

at 10:57
The toxic drug crisis that is now killing an average of 10 Ontarians every day will be the focus of a media conference organized by the Registered Nurses' Association of Ontario (RNAO) to close Nursing Week. While Nursing Week (May 6-12) is mainly...

at 10:53
Co-founder and CEO, Andrew Mignatti, of healthcare technology company, careviso, spoke at The Third Virtual National Health Care Transparency and No Surprises Act Summit. Mignatti's presentation centered around the existing transparency legislation...

at 10:45
Texas Children's Hospital is pleased to announce the new executive leadership structure at the Texas Children's Heart Center, which has been ranked number one in the nation for pediatric cardiology and heart surgery by U.S. News and World Report for...



News published on and distributed by: